A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer

详细信息    查看全文

• 作者：Kathrin Schwager (1)
  Alessandra Villa (1)
  Christoph R?sli (2)
  Dario Neri (2)
  Maria R?sli-Khabas (3)
  Gerhard Moser (3)
  
• 刊名：Head & Neck Oncology
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：3
• 期：1
• 全文大小：1215KB
• 参考文献：1. Schliemann C, Neri D: Antibody-based targeting of the tumor vasculature. / Biochim Biophys Acta 2007, 1776:175-92.
  2. Schrama D, Reisfeld RA, Becker JC: Antibody targeted drugs as cancer therapeutics. / Nat Rev Drug Discov 2006, 5:147-59. CrossRef
  3. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D: Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. / J Biol Chem 1998, 273:21769-1776. CrossRef
  4. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, Rosli C, Borsi L, Neri D: A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. / Int J Cancer 2008, 122:2405-413. CrossRef
  5. Brack SS, Silacci M, Birchler M, Neri D: Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. / Clin Cancer Res 2006, 12:3200-208. CrossRef
  6. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B, Zardi L, Paganelli G, Mariani G, / et al.: Expression of the oncofetal ED-B containing fibronectin isoform in hematologic tumors enables ED-B targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. / Blood 2009,113(10):2265-4. CrossRef
  7. Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, / et al.: The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. / Eur J Cancer 2010, 46:2926-935. CrossRef
  8. Birchler MT, Milisavlijevic D, Pfaltz M, Neri D, Odermatt B, Schmid S, Stoeckli SJ: Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. / Laryngoscope 2003, 113:1231-237. CrossRef
  9. Birchler MT, Thuerl C, Schmid D, Neri D, Waibel R, Schubiger A, Stoeckli SJ, Schmid S, Goerres GW: Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment. / Otolaryngol Head Neck Surg 2007, 136:543-48. CrossRef
  10. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D, Zardi L: Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. / Int J Cancer 2002, 102:75-5. CrossRef
  11. Frey K, Zivanovic A, Schwager K, Neri D: Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation. / Integr Biol (Camb) 2011,3(4):468-8. CrossRef
  12. Pedretti M, Soltermann A, Arni S, Weder W, Neri D, Hillinger S: Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. / Lung Cancer 2009, 64:28-3. CrossRef
  13. Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D: Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. / Leuk Res 2009, 33:1718-722. CrossRef
  14. Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L: Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. / Int J Cancer 1994, 59:11-6. CrossRef
  15. Tijink BM, Perk LR, Budde M, Stigter-van Walsum M, Visser GW, Kloet RW, Dinkelborg LM, Leemans CR, Neri D, van Dongen GA: (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. / Eur J Nucl Med Mol Imaging 2009, 36:1235-244. CrossRef
  
• 作者单位：Kathrin Schwager (1)
  Alessandra Villa (1)
  Christoph R?sli (2)
  Dario Neri (2)
  Maria R?sli-Khabas (3)
  Gerhard Moser (3)
  
  1. Philochem AG, c/o ETH Zurich, Institute of Pharmaceutical Sciences, Wolfgang-Pauli-Str. 10 HCI E520, CH-8093, Zurich, Switzerland
  2. Institute of Pharmaceutical Sciences, ETH Zurich, Wolfgang-Pauli-Strasse 10, CH-8093, Zurich, Switzerland
  3. Department of Otorhinolaryngology, Paracelsus Medical University, Federal Hospital Salzburg, Muellner-Hauptstrasse 48, A-5020, Salzburg, Austria
  

文摘

Background The antibody-based targeted delivery of bioactive molecules to tumour vasculature is an attractive avenue to concentrate therapeutic agents at cancer sites, while sparing normal organs. L19, F8 and F16 are three fully human monoclonal antibodies, specific to splice isoforms of fibronectin and tenascin-C, which bind to sites of active tissue remodeling and which are currently in Phase I and II clinical trials as radio-immunoconjugates and immunocytokines in patients with cancer and arthritis. In this article, we report the first comparative analysis of expression patterns for the extra domains EDB and EDA of fibronectin and A1 of tenascin-C in both primary and metastatic head and neck cancer lesions. Methods We performed a comparative immunofluorescence analysis with the L19, F8 and F16 antibodies in 40 freshly frozen human head and neck cancer specimens. Results On average, F8 and F16 exhibited similar staining intensities, which were typically stronger than L19. Interestingly, some specimens exhibited striking differences in staining by the three antibodies. Conclusions These results suggests that an individualized treatment procedure (e.g., choice of L19, F8 or F16 based on immuno-PET or immunofluorescence procedure) may represent the most logical avenue for offering the best possible antibody to any given patient.